Skip to main content
. 2023 Dec 6;43(4):616–632. doi: 10.1002/npr2.12403

TABLE 2.

Primary, secondary, and tertiary diagnoses of patients.

Diagnosis Primary Secondary Tertiary
n (%) n (%) n (%)
Agoraphobia 0 (0.00) 3 (0.22) 3 (0.22)
Anxiety 120 (8.71) 111 (8.06) 25 (1.81)
Attention‐deficit/hyperactivity disorder 22 (1.60) 14 (1.02) 3 (0.22)
Autistic spectrum disorder 19 (1.38) 8 (0.58) 12 (0.87)
Cancer pain 11 (0.80) 7 (0.51) 0 (0.00)
Chemotherapy‐induced nausea and vomiting 6 (0.44) 1 (0.07) 1 (0.07)
Chronic non‐cancer pain 394 (28.59) 80 (5.81) 1 (0.94)
Cluster headaches 3 (0.22) 1 (0.07) 0 (0.00)
Complex regional pain syndrome 8 (0.58) 3 (0.22) 2 (0.15)
Crohn's disease 27 (1.96) 5 (0.36) 2 (0.15)
Depression 54 (3.92) 50 (3.63) 34 (2.47)
Eating disorder 1 (0.07) 3 (0.22) 4 (0.29)
Ehlers‐Danlos Syndrome 42 (3.05) 23 (1.67) 9 (0.65)
Endometriosis 1 (0.07) 1 (0.07) 0 (0.00)
Epilepsy adult 26 (1.89) 1 (0.07) 1 (0.07)
Fibromyalgia 162 (11.76) 73 (5.30) 7 (0.51)
Headache 2 (0.15) 8 (0.58) 2 (0.15)
Inflammatory arthritis 52 (3.77) 0 (0.00) 0 (0.00)
Insomnia 30 (2.18) 31 (2.25) 22 (1.60)
Migraine 38 (2.76) 20 (1.45) 8 (0.58)
Multiple sclerosis 36 (2.61) 3 (0.22) 0 (0.00)
Neuropathic pain 136 (9.87) 49 (3.56) 7 (0.51)
Obsessive‐compulsive disorder 2 (0.15) 3 (0.22) 1 (0.07)
Osteoarthritis 51 (3.70) 5 (0.36) 4 (0.29)
Palliative care 55 (3.99) 1 (0.07) 0 (0.00)
Parkinson's 12 (0.87) 1 (0.07) 0 (0.00)
Post‐traumatic stress disorder 54 (3.92) 3 (0.22) 10 (0.73)
Rare and challenging skin condition 5 (0.36) 13 (0.94) 0 (0.00)
Tourette's syndrome 2 (0.15) 3 (0.22) 0 (0.00)
Trigeminal neuralgia 1 (0.07) 3 (0.22) 1 (0.07)
Ulcerative colitis 6 (0.44) 3 (0.07) 0 (0.00)

Note: The indications for cannabis‐based medicinal product treatment and the number of patients with the corresponding indication were recorded.

Abbreviation: n, number of patients.